AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical significance for its primary endpoint in AL amyloidosis, although it showed promise ...

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Tempus AI (TEM) has recently secured FDA clearance for its Tempus ECG-Low EF software, an innovative AI-driven product aiding cardiovascular assessments. This development aligns with TEM’s aim to ...